Financial Partners Group LLC Increases Stock Position in Novo Nordisk A/S $NVO

Key Points

• Financial Partners Group LLC increased its stake in Novo Nordisk A/S by 43.7% in the second quarter, owning 26,308 shares valued at approximately $1,816,000.
• Several institutional investors have also made significant modifications to their holdings in Novo Nordisk, with 11.54% of the stock now owned by hedge funds and other institutional investors.
• Novo Nordisk A/S reported earnings per share of $0.97 for the most recent quarter, exceeding analysts' expectations, while also cutting its dividend payout ratio to 22.53%.

Financial Partners Group LLC lifted its stake in Novo Nordisk A/S (NYSE:NVO - Free Report) by 43.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 26,308 shares of the company's stock after purchasing an additional 8,002 shares during the period. Financial Partners Group LLC's holdings in Novo Nordisk A/S were worth $1,816,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. North Capital Inc. purchased a new stake in shares of Novo Nordisk A/S in the 1st quarter worth about $27,000. Copeland Capital Management LLC lifted its position in shares of Novo Nordisk A/S by 184.8% in the 1st quarter. Copeland Capital Management LLC now owns 393 shares of the company's stock worth $27,000 after purchasing an additional 255 shares during the period. Stone House Investment Management LLC purchased a new stake in shares of Novo Nordisk A/S in the 1st quarter worth about $30,000. Disciplina Capital Management LLC lifted its position in shares of Novo Nordisk A/S by 162.3% in the 1st quarter. Disciplina Capital Management LLC now owns 480 shares of the company's stock worth $33,000 after purchasing an additional 297 shares during the period. Finally, Spirit of America Management Corp NY purchased a new stake in shares of Novo Nordisk A/S in the 1st quarter worth about $35,000. 11.54% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

NVO has been the subject of several research analyst reports. HSBC cut shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating and set a $57.00 target price for the company. in a research report on Thursday, July 31st. Rothschild Redb raised shares of Novo Nordisk A/S from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, September 16th. UBS Group cut shares of Novo Nordisk A/S from a "buy" rating to a "neutral" rating in a research report on Tuesday, August 5th. Berenberg Bank raised shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research report on Wednesday, September 17th. Finally, BNP Paribas Exane raised shares of Novo Nordisk A/S from an "underperform" rating to a "neutral" rating and set a $54.00 price target for the company in a research report on Wednesday, August 13th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $81.00.

Novo Nordisk A/S Trading Down 0.8%

Shares of NYSE NVO opened at $55.61 on Friday. The stock has a market cap of $248.30 billion, a P/E ratio of 15.28, a price-to-earnings-growth ratio of 2.11 and a beta of 0.66. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.78 and a quick ratio of 0.56. Novo Nordisk A/S has a 1 year low of $45.05 and a 1 year high of $121.34. The firm has a 50-day moving average of $56.03 and a 200 day moving average of $64.46.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported $0.97 earnings per share for the quarter, beating analysts' consensus estimates of $0.93 by $0.04. The business had revenue of $11.69 billion during the quarter, compared to analyst estimates of $77.51 billion. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. As a group, sell-side analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The company also recently disclosed a semi-annual dividend, which was paid on Tuesday, August 26th. Shareholders of record on Monday, August 18th were paid a dividend of $0.4119 per share. This represents a yield of 240.0%. The ex-dividend date was Monday, August 18th. Novo Nordisk A/S's dividend payout ratio (DPR) is currently 22.53%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.